Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Lung Cancer|Hepatocellular Cancer|Colorectal Cancer|Pancreatic Cancer|Renal Cancer
Interventions: DRUG: NIS793|DRUG: PDR001
Sponsor: Novartis Pharmaceuticals